SEO URLwww.firestrike.ai/deals/arcellx-gilead-sciences-acquisition-2026-2

acquisitionAnnounced · Feb 23, 2026biotechnologySource · Community DiscussionsArticle · Factual

Arcellx · Gilead Sciences

Gilead Sciences acquires Arcellx

David Najork · Founding Software Engineer

Published Apr 29, 2026 · Updated Apr 29, 2026 · 1 min read

ShareX LinkedIn Email

Deal value

$7.8B

Target

Arcellx

NASDAQ: ACLX · Redwood City, California

Acquirer

Gilead Sciences

Full Acquisition

Status

Announced

Gilead Sciences agreed to acquire Arcellx. Reported deal value: $7.8B. Status: Announced. Sector: biotechnology. Target headquarters context: Redwood City, California, United States.

This page summarizes publicly available information about the transaction as of 2026-02-23. Figures and status may change as filings and press coverage update.

Leave a Comment Today, February 23rd, 2026, Gilead Sciences announced a definitive agreement to acquire Arcellx in a transaction valued at approximately $7.8 billion , providing Gilead with full ownership of anitocabtagene autoleucel , an investigational BCMA-directed CAR -T therapy for patients with relapsed or refractory multiple myeloma

Deal timeline

Announced

Feb 23, 2026 · bioinformant.com

Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.

Sector context

This transaction is classified in biotechnology with a reported deal value of $7.8B. Figures and status may change as sources update.

Sources: bioinformant.com · Primary article · FireStrike proprietary index